EPIGEN INC /DE
SC 13D, 2000-07-11
IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES
Previous: EPIGEN INC /DE, SC 13D, 2000-07-11
Next: INTERNATIONAL THERMAL PACKAGING INC, 10-K, 2000-07-11



                       SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549


                                  SCHEDULE 13D
                                 (Rule 13d-101)


            INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT
           TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO
                                  RULE 13d-2(a)


                               (Amendment No.1)



                                  Epigen, Inc.
                                ----------------
                                (Name of Issuer)


                                  Common Stock
                         ------------------------------
                         (Title of Class of Securities)


                                  294259 10 G
                                 --------------
                                 (CUSIP Number)


       Colin K. Harley, Harley & Deickler, P.O. Box 264 Woodbury, CT 06798
                                  203-263-2469
       -------------------------------------------------------------------
                  (Name, Address and Telephone Number of Person
                Authorized to Receive Notices and Communications)


                                  June 28, 2000
             -------------------------------------------------------
             (Date of Event Which Requires Filing of This Statement)


          If the filing person has previously  filed a statement on Schedule 13G
to report the  acquisition  that is subject to this  Schedule 13D, and is filing
this  schedule  because  of Rule  13d-1(e),  13d-1(f)  or  13d-1(g),  check  the
following box [_].

     Note.  Schedules  filed in paper format shall include a signed original and
     five copies of the schedule,  including all exhibits. See Rule 13d-7(b) for
     the other parties to whom copies are to be sent.

                                                             (Page 1 of 1 Pages)
<PAGE>

CUSIP NO. 294259 10 G                  13D                  (Page 2  of 2 Pages)


1.  NAMES OF REPORTING PERSONS - W. James Tozer, Jr.
    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)


2.  CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*                     (a)[_]
                                                                          (b)[X]


3.  SEC USE ONLY


4.  SOURCE OF FUNDS* - PF


5.  CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT
    TO ITEM 2(D) OR 2(E)                                                     [_]


6.  CITIZENSHIP OR PLACE OF ORGANIZATION  -  UNITED STATES


NUMBER OF                  7.  SOLE VOTING POWER  -  2,422,308
SHARES
BENEFICIALLY               8.  SHARED VOTING POWER  -  0
OWNED BY
EACH                       9.  SOLE DISPOSITIVE POWER  - 2,422,308
REPORTING
PERSON WITH               10. SHARED DISPOSITIVE POWER  -  0



11. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON - 2,422,308


12. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES
    CERTAIN SHARES*                                                          [_]


13. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) - 19.25%


14. TYPE OF REPORTING PERSON* - IN

                                    SIGNATURE

          After reasonable inquiry and to the best of my knowledge and belief, I
certify that the information  set forth in this statement is true,  complete and
correct.

                                            7/5/2000
                                            --------
                                            (Date)


                                            /s/ W. James Tozer, Jr.
                                            -----------------------
                                            (Signature)

                                            /s/ W. James Tozer, Jr.
                                            -----------------------
                                            (Name/Title)



© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission